Keros Therapeutics (KROS) Return on Capital Employed (2020 - 2026)
Keros Therapeutics' (KROS) quarterly Return on Capital Employed came in at 12.99% in Q4 2025, up 4997.0% YoY from 0.25% in Q4 2024, and up 116.41% on a QoQ basis from 6.0% in Q3 2025.
Keros Therapeutics (KROS) Return on Capital Employed (2020 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 6 years of Return on Capital Employed data on file, last reported at 12.99% in Q4 2025.
- Quarterly Return on Capital Employed rose 4997.0% year-over-year to 12.99% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 12.99% (up 4997.0% YoY) and the FY2025 annual result came in at 14.8%, up 6009.0% from the prior year.
- Return on Capital Employed grew to 12.99% in Q4 2025, from 6.0% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 12.99% in Q4 2025 to a low of 52.49% in Q4 2023.
- A 5-year average of 28.5% and a median of 37.04% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 1920 bps — and 2025, when it surged 4997 bps.
- Tracing KROS's Return on Capital Employed over 5 years: stood at 24.43% in 2021, then sank by 79 bps to 43.63% in 2022, then slipped by 20 bps to 52.49% in 2023, then gained by 30 bps to 36.98% in 2024, then soared by 135 bps to 12.99% in 2025.
- The last three Return on Capital Employed figures came in at 12.99% (Q4 2025), 6.0% (Q3 2025), and 0.04% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | -38.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.39% |
| Dec 31, 2025 | 12.99% |
| Sep 30, 2025 | 6.00% |
| Jun 30, 2025 | 0.04% |
| Mar 31, 2025 | -1.56% |
| Dec 31, 2024 | -36.98% |
| Sep 30, 2024 | -41.80% |
| Jun 30, 2024 | -42.00% |
| Mar 31, 2024 | -43.88% |
| Dec 31, 2023 | -52.49% |
| Sep 30, 2023 | -47.89% |
| Jun 30, 2023 | -39.56% |
| Mar 31, 2023 | -39.23% |
| Dec 31, 2022 | -43.63% |
| Sep 30, 2022 | -38.45% |
| Jun 30, 2022 | -37.09% |
| Mar 31, 2022 | -27.72% |
| Dec 31, 2021 | -24.43% |
| Sep 30, 2021 | -28.71% |
| Jun 30, 2021 | -23.27% |